Background and Aims: High fractional exhaled nitric oxide (FeNO) levels have been regarded as an indicator of asthma exacerbation. However, little is known about the effect of high FeNO levels on short-term course of lung function. The aim of this study was to assess whether high FeNO levels (> 35 ppb) would predict the short-term worsening of lung function.
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Background and Aims: High fractional exhaled nitric oxide (FeNO) levels have been regarded as an indicator of asthma exacerbation. However, little is known about the effect of high FeNO levels on short-term course of lung function. The aim of this study was to assess whether high FeNO levels (> 35 ppb) would predict the short-term worsening of lung function.
Methods: This was a multicentre prospective observational study.
Subjects included asthmatic patients who had routine check-ups at each institution from April 2015 to December 2016. Patients received standard treatment, including ICS and other medications, according to the asthma guidelines and the medications were not changed for at least 3 months.
The asthma control test (ACT), spirometry, and forced oscillation technique (FOT) were performed before and after observation period. The patients were classified into high and low FeNO groups (FeNO ≥ 35 ppb or < 35 ppb) based on the baseline FeNO levels and the results were compared between the 2 groups.
Results: One hundred and four patients (mean age, 52 years and 49 males) completed the study without exacerbation. Overall, FeNO levels significantly decreased (mean, ppb: 34.7 to 31.1; P = 0.0243). However, there was no change in the ACT scores or lung function. A comparison between the groups revealed that FeNO improved significantly in the high FeNO group but not in the low FeNO group (mean, ppb: 58.9 to 44.7 and 23.9 to 25.1, respectively; P < 0.001). The difference between respiratory resistance at 5 Hz and 20 Hz (R5-R20), a parameter of FOT, significantly worsened in the high FeNO group but not in the low . We hypothesize that delays in taking appropriate action steps may contribute to the failure of AAPs. Thus, the aim of this study was to evaluate the effectiveness of more rapid escalations of AAPs in the management of acute asthma exacerbations (AAEs).
Methods: This is a before Vs after study of consecutive adult patients attending an asthma clinic all of whom had previously received training in AAPs. During the intervention period, we actively promoted the rapid escalation of self-management steps during AAEs with a 'KILAT' (lightning) AAP training program. We compared patient behaviour and clinical outcomes in AAEs before Vs after implementing the KILAT AAP. APP failure was defined as any unscheduled doctor and/or hospital visit for an AAE.
Results: When the KILAT APP was taught to the first 297 patients only 78 (26%) remembered it. After several iterations, this improved to 52%. The rapid escalation KILAT APP was applied in 418 AAEs. Before the KILAT escalation plan was implemented the APP failure rate was 109/342 (32%, 95%CI: 27%-37%) afterwards it was 111/418 (27%, 95% CI: 22%-31%) (P>0.05). Rates of emergency department and/or hospital admissions were reduced from 56/342 (16%, 95%CI: 12%-20%) to 47/418 (11%, 95%CI: 8%-14%), P < 0.05. There was also a reduction in the % of patients who took oral prednisolone during AAEs from 64% (95%CI: 60%-69%) to 15% (95%CI:12%-18%).
Conclusion:
We conclude that, despite poor adherence, faster escalations may improve the effectiveness of AAP in treating asthma exacerbations. Following our intervention there was a marked reduction in the use of oral steroid bursts. More robust studies are needed on the impact of adherence and timeliness on the effectiveness of AAPs. are a class of monohydroxy fatty acids that are metabolized by arachidonic acid (AA). They may be involved in the pathogenesis of asthma, but little is known about their potential roles in allergic bronchopulmonary aspergillosis (ABPA). This study was performed to evaluate serum HETEs in ABPA patients and to observe the changes of HETEs levels during treatment.
Methods: Sera from ABPA (N = 20), fungal associated asthma (FAA, N = 15), non-fungal associated asthma (NFAA, N = 23) patients and the healthy controls (N = 12) were assessed for 14 eicosanoids by using ultra-high performance liquid chromatography-quadruple-time of flight/MS (UHPLC-Q-TOF/MS). In addition, sera from 12 ABPA patients were collected at 1, 2, 3, 6 months after treatment in our hospital.
Results: Compared with FAA and NFAA subjects, ABPA subjects expressed lower levels of serum AA, 15(S)-HPETE, 12(S)-HPETE and 5 (S)-HPETE (P < 0.05). However, their levels of serum 15(S)-HETE and 12(S)-HETE were higher than in NFAA subjects and HC groups (P < 0.05). After treatment, the serum levels of 15(S)-HETE, 12(S)-HETE, 11(S)-HETE, 8(S)-HETE and 5(S)-HETE in ABPA subjects all decreased with the decrease of Af. sIgE concentration. Additionally, in APBA subjects, there was a positive correlation between serum AA and tIgE (rho = 0.649; P < 0.05). Serum 11(S)-HETE was positively correlated with Af. sIgE, FVC and FEV1 respectively (rho = 0.659, P < 0.05; rho = 0.753, P < 0.01; rho = 0.800, P < 0.01). Serum 15(S)-HETE was positively correlated with the ratio of FEV1/FVC (rho = 0.632, P < 0.05). Simultaneously, both 12(S)-HETE and 15(S)-HETE showed a positive correlation with peripheral blood eosinophil count (rho = 0.683, P < 0.05; rho = 0.681, P < 0.05). 
